Tag: precision oncology
mRNA Cancer Vaccines Harness Unexpected Immune Backup System, Study Finds
Researchers have identified an unexpected immune cell type recruited by mRNA cancer vaccines, challenging conventional understanding and potentially enabling more…
KRAS-G12D inhibitor shows promise in advanced pancreatic cancer: phase 1b/2 trial results
A phase 1b/2 trial published in Nature Medicine demonstrates that HRS-4642, a targeted KRAS-G12D inhibitor combined with chemotherapy, achieves encouraging…
Light-Activated Molecular Switch Reawakens Dormant Cancer Cells, ETH Zurich Study Shows
ETH Zurich scientists have engineered a light-controlled molecular switch that selectively destroys stress hormone receptors in dormant cancer cells, potentially…
Plasma histidine levels linked to immunotherapy survival: a metabolomic breakthrough
A new study in Nature Medicine identifies elevated plasma histidine as a metabolic predictor of improved immunotherapy survival across five…
Molecular Tumor Boards Show Promise in Bridging Precision Oncology’s Access Gap
A meta-analysis in PLOS Medicine shows that molecular tumor boards—multidisciplinary teams interpreting genomic data—improve precision oncology outcomes. But resource constraints…
Correction Published for ABBV-706 Phase 1 Trial in Small Cell Lung Cancer and Solid Tumors
Nature Medicine has published an author correction to the ABBV-706 phase 1 trial, a SEZ6-targeting antibody-drug conjugate for advanced small…
Tailored drug combinations show promise against treatment-resistant melanoma in preclinical study
Researchers at MD Anderson Cancer Center have developed a strategy to match drug combinations to tumor biomarkers in treatment-resistant melanoma,…
Deep Learning Unlocks Molecular Secrets in Meningioma Diagnosis Without Genetic Testing
A new study demonstrates that artificial intelligence trained on routine pathology slides can identify meningioma molecular subtypes and predict patient…